Skip to main content

Topic

Biosimilars

851 published works

  1. Big Molecule Watch

    Teva and Polpharma Biologics Announce Global Licensing Agreement for Ocrelizumab Biosimilar for Multiple Sclerosis

    By Zachariah Holmes

    On July 9, 2026, Teva Pharmaceuticals International GmbH (“Teva”) and Polpharma Biologics International AG (“Polpharma Biologics”) announced a global licensing agreement under which Teva will obtain exclusive rights to commercialize…

  2. Big Molecule Watch

    Harrow Re-Launches BYOOVIZ (ranibizumab-nuna) in the United States

    By Grace Truong

    On July 1, 2026, Harrow announced the commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTIS (ranibizumab).   BYOOVIZ was developed by Samsung Bioepis Co., Ltd. (“Samsung Bioepis”). BYOOVIZ was…

  3. Big Molecule Watch

    Celltrion and Teva’s TRUXIMA® Becomes First Interchangeable Rituximab Biosimilar in U.S.

    By Riley Wyberg

    On July 1, 2026, Celltrion announced that the FDA had granted interchangeability designation to TRUXIMA® (rituximab-abbs), Celltrion and Teva’s biosimilar to Genentech’s RITUXAN®.  With this designation, TRUXIMA® became the first…

  4. Big Molecule Watch

    Janssen Files BPCIA Complaint Against Alvotech Related to Golimumab Biosimilar

    By Gabriella Montes|Wendy Leben

    On June 19, 2026, Janssen Biotech, Inc. and Janssen Sciences Ireland UC (collectively, “Janssen”) filed a BPCIA Complaint in the U.S. District Court for the Eastern District of Virginia against…

  5. Big Molecule Watch

    FDA Approves Lupin’s Ranibizumab Biosimilar

    By Alex Pressman

    On June 5, Lupin announced that the U.S. Food and Drug Administration (“FDA”) approved RANLUSPEC, a ranibizumab biosimilar to Genentech’s LUCENTIS®. RANLUSPEC, which received European Marketing Authorization earlier this year,…

  6. Big Molecule Watch

    Alvotech’s BLA for Vedolizumab Biosimilar First to be Accepted by FDA

    By Zachariah Holmes

    On June 8, Alvotech announced that the U.S. Food and Drug Administration (“FDA”) has accepted Alvotech’s Biologics License Application (“BLA”) for AVT16, a proposed interchangeable biosimilar to Takeda’s ENTYVIO (vedolizumab),…

  7. Big Molecule Watch

    Chime Biologics and Daewoong Pharmaceutical Partner on Dupilumab Biosimilar

    By Timothy Beavers

    On June 2, 2026, Chime Biologics and Daewoong Pharmaceutical announced a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Sanofi and Regeneron’s DUPIXENT. Chime…

  8. Big Molecule Watch

    Boan Biotech Submits BLA to FDA for Two Denosumab Biosimilars

    By Alice Yoon

    On May 29, 2026, Boan Biotech announced that it submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for BA6101 (denosumab; injection 60 mg) and…

  9. Big Molecule Watch

    Polpharma and Tuteur Enter License for the Commercialization of a Biosimilar Targeting Autoimmune Diseases in Latin America

    By Riley Wyberg

    On May 22, 2026, Polpharma Biologics announced that it had entered into an exclusive licensing agreement with Tuteur to commercialize a biosimilar targeting autoimmune diseases across Latin America, excluding Brazil. …

  10. Big Molecule Watch

    Samsung Bioepis Launches OPUVIZ in Europe

    By Harrison Gunn

    On May 29, 2026, Samsung Bioepis Co., Ltd. announced the European launch of OPUVIZ, a biosimilar referencing EYLEA (aflibercept). OPUVIZ will be available as a 40 mg/mL solution for injection.…